Literature DB >> 30352903

Targeting Resistance to Targeted Therapies: Combating a Resilient Foe.

Siddhartha Devarakonda1,2, Ramaswamy Govindan3,2.   

Abstract

While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.See related article by Le et al., p. 6195. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30352903      PMCID： PMC6295273          DOI： 10.1158/1078-0432.CCR-18-3178

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.

Authors:  June-Koo Lee; Junehawk Lee; Sehui Kim; Soyeon Kim; Jeonghwan Youk; Seongyeol Park; Yohan An; Bhumsuk Keam; Dong-Wan Kim; Dae Seog Heo; Young Tae Kim; Jin-Soo Kim; Se Hyun Kim; Jong Seok Lee; Se-Hoon Lee; Keunchil Park; Ja-Lok Ku; Yoon Kyung Jeon; Doo Hyun Chung; Peter J Park; Joon Kim; Tae Min Kim; Young Seok Ju
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544

Review 2.  Resisting Resistance: Targeted Therapies in Lung Cancer.

Authors:  Jessica J Lin; Alice T Shaw
Journal:  Trends Cancer       Date:  2016-07

3.  EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.

Authors:  Janyaporn Phuchareon; Frank McCormick; David W Eisele; Osamu Tetsu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

4.  Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.

Authors:  Zhe Yang; Nong Yang; Qiuxiang Ou; Yi Xiang; Tao Jiang; Xue Wu; Hua Bao; Xiaoling Tong; Xiaonan Wang; Yang W Shao; Yunpeng Liu; Yan Wang; Caicun Zhou
Journal:  Clin Cancer Res       Date:  2018-03-05       Impact factor: 12.531

5.  Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Authors:  Xiuning Le; Sonam Puri; Marcelo V Negrao; Monique B Nilsson; Jacqulyne Robichaux; Theresa Boyle; J Kevin Hicks; Katherine L Lovinger; Emily Roarty; Waree Rinsurongkawong; Ming Tang; Huiying Sun; Yasir Elamin; Lara C Lacerda; Jeff Lewis; Jack A Roth; Stephen G Swisher; J Jack Lee; William N William; Bonnie S Glisson; Jianjun Zhang; Vassiliki A Papadimitrakopoulou; Jhanelle E Gray; John V Heymach
Journal:  Clin Cancer Res       Date:  2018-09-18       Impact factor: 12.531

6.  Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Authors:  Geoffrey R Oxnard; Yuebi Hu; Kathryn F Mileham; Hatim Husain; Daniel B Costa; Philip Tracy; Nora Feeney; Lynette M Sholl; Suzanne E Dahlberg; Amanda J Redig; David J Kwiatkowski; Michael S Rabin; Cloud P Paweletz; Kenneth S Thress; Pasi A Jänne
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

7.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Authors:  Aaron N Hata; Matthew J Niederst; Hannah L Archibald; Maria Gomez-Caraballo; Faria M Siddiqui; Hillary E Mulvey; Yosef E Maruvka; Fei Ji; Hyo-eun C Bhang; Viveksagar Krishnamurthy Radhakrishna; Giulia Siravegna; Haichuan Hu; Sana Raoof; Elizabeth Lockerman; Anuj Kalsy; Dana Lee; Celina L Keating; David A Ruddy; Leah J Damon; Adam S Crystal; Carlotta Costa; Zofia Piotrowska; Alberto Bardelli; Anthony J Iafrate; Ruslan I Sadreyev; Frank Stegmeier; Gad Getz; Lecia V Sequist; Anthony C Faber; Jeffrey A Engelman
Journal:  Nat Med       Date:  2016-02-01       Impact factor: 53.440

8.  Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.

Authors:  Rahul Nahar; Weiwei Zhai; Tong Zhang; Angela Takano; Alexis J Khng; Yin Yeng Lee; Xingliang Liu; Chong Hee Lim; Tina P T Koh; Zaw Win Aung; Tony Kiat Hon Lim; Lavanya Veeravalli; Ju Yuan; Audrey S M Teo; Cheryl X Chan; Huay Mei Poh; Ivan M L Chua; Audrey Ann Liew; Dawn Ping Xi Lau; Xue Lin Kwang; Chee Keong Toh; Wan-Teck Lim; Bing Lim; Wai Leong Tam; Eng-Huat Tan; Axel M Hillmer; Daniel S W Tan
Journal:  Nat Commun       Date:  2018-01-15       Impact factor: 14.919
  8 in total
  1 in total

1.  Selective in vitro anti-cancer activity of non-alkylating minor groove binders.

Authors:  Ryan J O Nichol; Abedawn I Khalaf; Kartheek Sooda; Omar Hussain; Hollie B S Griffiths; Roger Phillips; Farideh A Javid; Colin J Suckling; Simon J Allison; Fraser J Scott
Journal:  Medchemcomm       Date:  2019-07-18       Impact factor: 3.597
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.